Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by EbbFlow88on Mar 23, 2023 10:11am
185 Views
Post# 35355997

RE:Results

RE:ResultsThat's a good summary gudisgood.

The growth of the last two years has been great. Back to back 20% growth in revenues. Hyperinflation is biting into that which explains the debt to hedge it and sounds like it can be put to use in 2023/24. Amal said they're busy but they haven't seen valuations change much and it's still competitive, which doesn't bode well for a ton of M&A but we shall see. Things can change quickly in this market and I find it hard to believe that with interest rates rising as fast as they have that companies are as solvent as GUD.

I'm sure the team is looking to diversify to a greater geographical area. The stock is way too cheap for their quality of earnings but it seems pretty obvious that the LatAm region is making investors skiddish.

Investing that cash in other areas may do a lot to comfort shareholders at some point. We'll see what management comes up with but for now we keep vacuuming up cheap shares. 


<< Previous
Bullboard Posts
Next >>